Compare NTLA & SUPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTLA | SUPX |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2016 | 2024 |
| Metric | NTLA | SUPX |
|---|---|---|
| Price | $13.82 | $17.57 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $17.32 | N/A |
| AVG Volume (30 Days) | ★ 6.5M | 289.6K |
| Earning Date | 02-26-2026 | 10-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,528,000.00 | $3,596,575.00 |
| Revenue This Year | $1.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.52 | 23.88 |
| 52 Week Low | $5.90 | $3.55 |
| 52 Week High | $28.25 | $76.50 |
| Indicator | NTLA | SUPX |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 53.11 |
| Support Level | $13.86 | $12.00 |
| Resistance Level | $17.09 | $14.99 |
| Average True Range (ATR) | 1.28 | 1.40 |
| MACD | 0.29 | 0.92 |
| Stochastic Oscillator | 52.80 | 51.65 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.